Information sur le laboratoire
Talat Bessissow (M.D./M.Sc.)
ChercheurUnité de recherche clinique
Département de médecine (McGill)
Profil de recherche
Mots-clés
Maladie de Crohn • colite ulcéreuse • cicatrisation des muqueuses • néoplasme • pathogenèseIntérêts de recherche
Ma recherche porte sur le rôle de la cicatrisation des muqueuses dans le traitement de la maladie inflammatoire chronique de l'intestin. Je m'intéresse également à l'identification des facteurs qui prédisent la rechute de la maladie.Membre de l'équipe
| Nom | Poste |
|---|
Dernières publications
- Soublette Figuera, A., Alessa, S., Brien, C., Hendrickson, M., Kasvis, P. & Bessissow, T. (2025). Effects of Ultra-Processed Foods and Food Additives on Disease Activity in Adults with Inflammatory Bowel Disease: A Scoping Review. Journal of clinical medicine, vol. 14.
- Pedicelli, A., Bessissow, T. & Afif, W. (2025). Personalizing IL-23 Inhibitor Therapy in IBD: Current Evidence and Future Directions in Therapeutic Drug Monitoring and Dose Optimization. Journal of clinical medicine, vol. 14.
- Al Alawi, S., Bessissow, T., Tsoukas, S., Ureña Campos, R., Lu, Y., Chen, Y.-I. & Jacques, J. (2025). Combination of underwater and traction-assisted endoscopic submucosal dissection: the perfect wedding for a challenging case. Endoscopy, vol. 57, p. E1233-E1234.
- Chatto, M., Alaskar, D., Ma, C., Yuan, Y., Vuyyuru, S. K., Bessissow, T., Narula, N., Danese, S., Peyrin-Biroulet, L., Singh, S., Jairath, V. & Sedano, R. (2025). Pharmacological management of upper gastrointestinal crohn's disease: A systematic review. Journal of Crohn's & colitis.
- Ongay, J., Candel, I., Bitton, A., Afif, W., Bessissow, T. & Lakatos, P. L. (2025). Case Report: Secukinumab (Interleukin-17 Inhibitor) and Ulcerative Colitis Flare - the Double-Edged Sword. Case reports in gastroenterology, vol. 19, p. 637-643.
- Drügg Hahn, G., Lakatos, P. L., Maedler-Kron, C., Marcus, V., Afif, W., Wild, G., Bitton, A., Flores, C., de Magalhães Francesconi, C. F. & Bessissow, T. (2025). Defining Fecal Calprotectin Cutoffs That Predict Endoscopic and Histologic Remission in Patients With Ulcerative Colitis. Inflammatory bowel diseases.
- Shehab, M., Alrashed, O., Alrashed, F., Alyousefi, R., Zoughlami, A., Lakatos, P., Allez, M., Jairath, V., Regueiro, M. & Bessissow, T. (2025). Comparative Efficacy of Medical Therapies in Reducing the Risk of Postoperative Recurrence in Crohn's Disease: A Systematic Review and Network Meta-Analysis. Inflammatory bowel diseases.
- Kritzinger, J., Kotrri, G., Lakatos, P. L., Bessissow, T. & Wild, G. (2025). The Role of Biomarkers in Surveillance of Ulcerative Colitis-Associated Colorectal Cancer: A Scoping Review. Journal of clinical medicine, vol. 14.
- Farkas, B., Resál, T., Lakatos, P. L., Bessissow, T., Limdi, J. K., Armuzzi, A., Bezzio, C., Savarino, E. V., Saibeni, S., Michalopoulos, G., Attauabi, M., Seidelin, J. B., Fousekis, F. S., Katsanos, K., Bacsur, P., Bálint, A., Ivány, E., Szepes, Z., Farkas, K. & Molnár, T. (2025). Upadacitinib is associated with better clinical and biochemical outcomes than tofacitinib in refractory, moderate-to-severe UC. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
- Shehab, M., Hassan, A. & Bessissow, T. (2025). Editorial: The Devil Is in the Detail-Interpreting the Findings of Network Meta-Analyses. Authors' Reply. Alimentary pharmacology & therapeutics.
Voir aussi
